UA88766C2 - Quinoline derivatives for the treatment of latent tuberculosis - Google Patents

Quinoline derivatives for the treatment of latent tuberculosis

Info

Publication number
UA88766C2
UA88766C2 UAA200511766A UAA200511766A UA88766C2 UA 88766 C2 UA88766 C2 UA 88766C2 UA A200511766 A UAA200511766 A UA A200511766A UA A200511766 A UAA200511766 A UA A200511766A UA 88766 C2 UA88766 C2 UA 88766C2
Authority
UA
Ukraine
Prior art keywords
treatment
latent tuberculosis
quinoline derivatives
tuberculosis
latent
Prior art date
Application number
UAA200511766A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Коэнраад Джозеф Лодевик Марсел Андриэс
Анил Коул
Original Assignee
Янссен Фармацевтика Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Н.В. filed Critical Янссен Фармацевтика Н.В.
Publication of UA88766C2 publication Critical patent/UA88766C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol

Abstract

The invention relates to use of a compound of formula (Ia) or (Ib) for the preparation of medicinal agent useful for the treatment of latent tuberculosis.
UAA200511766A 2004-12-24 2005-12-09 Quinoline derivatives for the treatment of latent tuberculosis UA88766C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04078529 2004-12-24

Publications (1)

Publication Number Publication Date
UA88766C2 true UA88766C2 (en) 2009-11-25

Family

ID=36736133

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200511766A UA88766C2 (en) 2004-12-24 2005-12-09 Quinoline derivatives for the treatment of latent tuberculosis

Country Status (9)

Country Link
JP (5) JP2006182755A (en)
KR (2) KR101301573B1 (en)
CN (1) CN101087608A (en)
BG (1) BG66437B1 (en)
EA (1) EA009779B1 (en)
ES (1) ES2362886T3 (en)
JO (1) JO2695B1 (en)
UA (1) UA88766C2 (en)
ZA (1) ZA200705160B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA97813C2 (en) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Fumarate salt of (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol
CN103664877A (en) * 2013-12-25 2014-03-26 重庆医药工业研究院有限责任公司 Quinoline, preparation method and application of quinoline
JP6997095B2 (en) * 2016-03-07 2022-02-03 ザ グローバル アライアンス フォー ティービー ドラッグ デベロップメント， インコーポレイテッド Antibacterial compounds and their use
CN109384716B (en) * 2017-08-11 2021-06-29 海创药业股份有限公司 Deuterated quinoline compound and preparation and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075024A (en) * 1991-11-27 2000-06-13 Sepracor Inc. Methods for treating infection using optically pure (S)-lomefloxacin
MXPA05001052A (en) * 2002-07-25 2005-04-08 Janssen Pharmaceutica Nv Quinoline derivatives and their use as mycobacterial inhibitors.
CN1976704B (en) * 2004-05-28 2012-12-05 詹森药业有限公司 Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases

Also Published As

Publication number Publication date
JP2013049704A (en) 2013-03-14
JP6426530B2 (en) 2018-11-21
JP2006182755A (en) 2006-07-13
JP2017141259A (en) 2017-08-17
BG109180A (en) 2006-06-30
ZA200705160B (en) 2008-09-25
EA200500802A1 (en) 2006-06-30
EA009779B1 (en) 2008-04-28
KR20130041872A (en) 2013-04-25
JO2695B1 (en) 2013-03-03
ES2362886T3 (en) 2011-07-14
KR20060073416A (en) 2006-06-28
JP2017141262A (en) 2017-08-17
BG66437B1 (en) 2014-07-31
CN101087608A (en) 2007-12-12
KR101301573B1 (en) 2013-09-04
JP2015157847A (en) 2015-09-03

Similar Documents

Publication Publication Date Title
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
EA200870193A1 (en) CYTOTOXIC AGENTS, INCLUDING NEW TOMAMYCIN DERIVATIVES, AND THEIR THERAPEUTIC APPLICATION
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
PT1940839E (en) Pyridopyrimidinone inhibitors of pi3kalpha
TW200728307A (en) Novel spirochromanone derivatives
MX2009007075A (en) Methods of use for cyclopamine analogs.
MY148634A (en) Pyridazinone derivatives
HK1186125A1 (en) Quinoline derivatives for the treatment of latent tuberculosis
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
HK1119699A1 (en) Pyridopyrimidinone inhibitors of pi3kalpha
NO20090175L (en) Stable laquinimod compositions
WO2006011050A3 (en) Pyridine derivatives
WO2007087548A3 (en) Chemical compounds
BR0312934A (en) 8-Hydroxy Quinoline Derivatives
CY1108738T1 (en) THERAPEUTIC AGENTS USEFUL FOR PREVENTION OF PAIN
TW200626553A (en) Novel compounds
TW200716529A (en) New compounds II
TW200639156A (en) New compounds
NO20083708L (en) 4-Phenyl-thiazole-5-carboxylic acid and 4-phenyl-thiazole-5-carboxylmides as PLK1 inhibitors
MXPA05012247A (en) New benzimidazole derivatives.
NZ592927A (en) PHOSPHODIESTERASE TYPE III (PDE III) INHIBITORS OR CA2+-SENSITIZING AGENTS such as pimobendan FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY
MY158069A (en) Tricyclic compound and pharmaceutical use thereof
UA88766C2 (en) Quinoline derivatives for the treatment of latent tuberculosis
WO2008004100A9 (en) Therapeutic compounds
MX2010001304A (en) Therapeutic compounds.